English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

TO THE READERSHIP: The purpose of the editorial in the May issue (1) was to bring to the attention of the readership a guidance document written collaboratively by 3 organizations, including the Society of Nuclear Medicine and Molecular Imaging (2). The decision to publish this document in the European Journal of Nuclear Medicine and Molecular Imaging was made collaboratively by the 3 organizations, as was the decision to publish the editorial in The Journal of Nuclear Medicine. Incidentally, we described clinical trials with these agents that are getting under way in the United States. We overlooked mentioning the availability of 2 ongoing Food and Drug Administration–authorized investigational new drug (IND) trials on high-activity 111 In-octreotide (IND no. 72,037) (3,4 )a nd 177 Lu-octreotate (IND no. 78,256) peptide receptor radionuclide therapies in the United States. These ongoing trials are available at the Excel Diagnostics and Nuclear Oncology Center in Houston, Texas.

Addendum to the Editorial “Joint Guidance on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors”